Split intein-mediated protein trans-splicing to express large dystrophins
Published version of a preprint
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More recent preclinical developments allow for expression of full-length dystrophins in DMD mouse models (reviewed in Bengtsson et al., 2025), which is achieved by splitting the entire coding sequence over two or three AAVs and using split intein pairs to rejoin the protein products (Tasfaout et al., 2024; Zhou et al., 2024).”
From Understanding Duchenne muscular dystrophy-associated brain pathology (2025) · cites this paper as Tasfaout et al., 2024
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Nucleotide sequence and organization of the adeno-associated virus 2 genome
Srivastava, A., Lusby, E. W., & Berns, K. I. (1983) · Journal of Virology · doi:10.1128/jvi.45.2.555-564.1983 · Cited by 721
Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990) · Nature · doi:10.1038/343180a0 · Cited by 623 · cited 1×
“England et al. reported that a patient carrying a deletion of 46% (exons 17–48) of the DMD gene was largely asymptomatic and remained ambulatory until the seventh decade while expressing a highly functional mini-dystrophin 43 .”
Inteins: nature's gift to protein chemists
Shah, N. H., & Muir, T. W. (2014) · Chem. Sci. · doi:10.1039/c3sc52951g · Cited by 404 · cited 1×
“More than 30 split inteins have been characterized 23 .”
Bengtsson, N. E., Hall, J. K., Odom, G. L., Phelps, M. P., Andrus, C. R., Hawkins, R. D., Hauschka, S. D., Chamberlain, J. R., & Chamberlain, J. S. (2017) · Nature Communications · doi:10.1038/ncomms14454 · Cited by 387
Self-citationWeinmann, J., Weis, S., Sippel, J., Tulalamba, W., Remes, A., El Andari, J., Herrmann, A.-K., Pham, Q. H., Borowski, C., Hille, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19230-w · Cited by 259
Self-citationEfficient in vivo gene expression by trans-splicing adeno-associated viral vectors
Lai, Y., Yue, Y., Liu, M., Ghosh, A., Engelhardt, J. F., Chamberlain, J. S., & Duan, D. (2005) · Nature Biotechnology · doi:10.1038/nbt1153 · Cited by 224
Self-citationTornabene, P., Trapani, I., Minopoli, R., Centrulo, M., Lupo, M., de Simone, S., Tiberi, P., Dell’Aquila, F., Marrocco, E., Iodice, C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4523 · Cited by 192
Cordier, L., Gao, G.-P., Hack, A. A., McNally, E. M., Wilson, J. M., Chirmule, N., & Sweeney, H. L. (2001) · Human Gene Therapy · doi:10.1089/104303401750061267 · Cited by 152 · cited 1×
“…potent CK8e tissue-specific expression cassette restricts expression to muscle, avoiding off-target expression in other organs, such as the liver, and further reduces potential immune reactions (the use of muscle-restricted promoters has been shown to minimize transgene immune responses 46,47 ).”
Koo, T., Popplewell, L., Athanasopoulos, T., & Dickson, G. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.164 · Cited by 104
Gene Therapy of mdx Mice With Large Truncated Dystrophins Generated by Recombination Using rAAV6
Odom, G. L., Gregorevic, P., Allen, J. M., & Chamberlain, J. S. (2011) · Molecular Therapy · doi:10.1038/mt.2010.205 · Cited by 95
Self-citationFull-Length Dystrophin Reconstitution with Adeno-Associated Viral Vectors
Lostal, W., Kodippili, K., Yue, Y., & Duan, D. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.210 · Cited by 77
Tornabene, P., Trapani, I., Centrulo, M., Marrocco, E., Minopoli, R., Lupo, M., Iodice, C., Gesualdo, C., Simonelli, F., Surace, E. M., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.004 · Cited by 25
Research works printed but not linked: 40
- Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V. & Rizvanov, A. A. Various AAV serotypes and their applications in gene therapy: an overview. Cells 12, 785 (2023). · DOI · Paper page
- Monaco, A. P. et al. Detection of deletions spanning the Duchenne muscular dystrophy locus using a tightly linked DNA segment. Nature 316, 842–845 (1985). · DOI · Paper page
- Kunkel, L. M. et al. Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature 322, 73–77 (1986). · DOI · Paper page
- Danialou, G. et al. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J. 15, 1655–1657 (2001). · DOI · Paper page
- Ervasti, J. M. & Campbell, K. P. Membrane organization of the dystrophin-glycoprotein complex. Cell 66, 1121–1131 (1991). · DOI · Paper page
- Ervasti, J. M. & Campbell, K. P. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. 122, 809–823 (1993). · DOI · Paper page
- Banks, G. B., Judge, L. M., Allen, J. M. & Chamberlain, J. S. The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet. 6, e1000958 (2010). · DOI · Paper page
- Gregorevic, P. et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med. 12, 787–789 (2006). · DOI · Paper page
- Ramos, J. N. et al. Development of novel micro-dystrophins with enhanced functionality. Mol. Ther. 27, 623–635 (2019). · DOI · Paper page
- Bostick, B. et al. AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy. J. Mol. Cell. Cardiol. 53, 217–222 (2012). · DOI · Paper page
- Harper, S. Q. et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253–261 (2002). · DOI · Paper page
- Wasala, L. P. et al. The implication of hinge 1 and hinge 4 in micro-dystrophin gene therapy for Duchenne muscular dystrophy. Hum. Gene Ther. https://doi.org/10.1089/hum.2022.180 (2022). · DOI
- Birch, S. M. et al. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy. Sci. Transl. Med. 15, eabo1815 (2023). · DOI
- Esposito, F. et al. Liver gene therapy with intein-mediated F8 trans-splicing corrects mouse haemophilia A. EMBO Mol. Med. 14, e15199 (2022). · DOI
- Li, Y. F. Split-inteins and their bioapplications. Biotechnol. Lett 37, 2121–2137 (2015). · DOI
- Padula, A. et al. Full-length ATP7B reconstituted through protein trans-splicing corrects Wilson disease in mice. Mol. Ther. Methods Clin. Dev. 26, 495–504 (2022). · DOI
- Li, J., Sun, W. C., Wang, B., Xiao, X. & Liu, X. Q. Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Hum. Gene Ther. 19, 958–964 (2008). · DOI · Paper page
- Carvajal-Vallejos, P., Pallissé, R., Mootz, H. D. & Schmidt, S. R. Unprecedented rates and efficiencies revealed for new natural split inteins from metagenomic sources. J. Biol. Chem. 287, 28686–28696 (2012). · DOI · Paper page
- Caspi, J., Amitai, G., Belenkiy, O. & Pietrokovski, S. Distribution of split DnaE inteins in cyanobacteria. Mol. Microbiol. 50, 1569–1577 (2003). · DOI · Paper page
- Shah, N. H., Dann, G. P., Vila-Perelló, M., Liu, Z. H. & Muir, T. W. Ultrafast protein splicing is common among cyanobacterial split inteins: implications for protein engineering. J. Am. Chem. Soc. 134, 11338–11341 (2012). · DOI · Paper page
- Abedi, M. R., Caponigro, G. & Kamb, A. Green fluorescent protein as a scaffold for intracellular presentation of peptides. Nucleic Acids Res. 26, 623–630 (1998). · DOI · Paper page
- Crudele, J. M. & Chamberlain, J. S. AAV-based gene therapies for the muscular dystrophies. Hum. Mol. Genet. 28, R102–R107 (2019). · DOI · Paper page
- Boer, J. M., de Meijer, E. J., Mank, E. M., van Ommen, G. B. & den Dunnen, J. T. Expression profiling in stably regenerating skeletal muscle of dystrophin-deficient mice. Neuromuscul. Disord. 12, S118–S124 (2002). · DOI
- Torres, L. F. B. & Duchen, L. W. The mutant mdx: inherited myopathy in the mouse. Morphological studies of nerves, muscles and end-plates. Brain 110, 269–299 (1987). · DOI · Paper page
- Bengtsson, N. E., Tasfaout, H., Hauschka, S. D. & Chamberlain, J. S. Dystrophin gene-editing stability is dependent on dystrophin levels in skeletal but not cardiac muscles. Mol. Ther. 29, 1070–1085 (2021). · DOI
- Lynch, G. S., Hinkle, R. T., Chamberlain, J. S., Brooks, S. V. & Faulkner, J. A. Force and power output of fast and slow skeletal muscles from mdx mice 6–28 months old. J. Physiol. 535, 591–600 (2001). · DOI · Paper page
- Pastoret, C. & Sebille, A. Mdx mice show progressive weakness and muscle deterioration with age. J. Neurol. Sci. 129, 97–105 (1995). · DOI · Paper page
- Stedman, H. H. et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352, 536–539 (1991). · DOI · Paper page
- Lefaucheur, J. P., Pastoret, C. & Sebille, A. Phenotype of dystrophinopathy in old mdx mice. Anat. Rec. 242, 70–76 (1995). · DOI · Paper page
- Chamberlain, J. S., Metzger, J., Reyes, M., Townsend, D. W. & Faulkner, J. A. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 21, 2195–2204 (2007). · DOI · Paper page
- El Andari, J. et al. Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders. Sci. Adv. 8, eabn4704 (2022). · DOI
- Tabebordbar, M. et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell 184, 4919–4938.e22 (2021). · DOI · Paper page
- Hartigan-O’Connor, D., Kirk, C. J., Crawford, R., Mule, J. J. & Chamberlain, J. S. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol. Ther. 4, 525–533 (2001). · DOI · Paper page
- Boennemann, C. G. et al. Dystrophin immunity after gene therapy for Duchenne’s muscular dystrophy. N. Engl. J. Med. 388, 2294–2296 (2023). · DOI
- Halbert, C. L., Allen, J. M. & Chamberlain, J. S. AAV6 vector production and purification for muscle gene therapy. Methods Mol. Biol. 1687, 257–266 (2018). · DOI
- Dellorusso, C., Crawford, R. W., Chamberlain, J. S. & Brooks, S. V. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J. Muscle Res. Cell Motil. 22, 467–475 (2001). · DOI · Paper page
- Gregorevic, P., Plant, D. R., Leeding, K. S., Bach, L. A. & Lynch, G. S. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. Am. J. Pathol. 161, 2263–2272 (2002). · DOI
- Kolwicz, S. C., Jr. & Tian, R. Assessment of cardiac function and energetics in isolated mouse hearts using 31P NMR spectroscopy. J. Vis. Exp. https://doi.org/10.3791/2069 (2010). · DOI
- Kolwicz, S. C. Jr. et al. Gene therapy rescues cardiac dysfunction in Duchenne muscular dystrophy mice by elevating cardiomyocyte deoxy-adenosine triphosphate. JACC Basic Transl. Sci. 4, 778–791 (2019). · DOI
- Rafael, J. A. et al. Forced expression of dystrophin deletion constructs reveals structure-function correlations. J. Cell Biol. 134, 93–102 (1996). · DOI · Paper page
Cited by
Understanding Duchenne muscular dystrophy-associated brain pathology
Verhaeg, M. A. T., Govaarts, R., & van Putten, M. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052302 · Cited by 5
Metadata
- Authors
- Tasfaout, H., Halbert, C. L., McMillen, T. S., Allen, J. M., Reyes, T. R., Flint, G. V., Grimm, D., Hauschka, S. D., Regnier, M., & Chamberlain, J. S.
- Venue
- Nature
- Published
- 2024-07-17
- Volume
- 632
- Issue
- 8023
- Pages
- 192-200
- ISSN
- 0028-0836
- 1476-4687
- Cited by
- 83
- References
- 15
- Language
- en
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.